TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Kivo Health raised $10 million in a Series A round led by Allumia Ventures, bringing its total financing to $16 million. The Seattle-based company plans to expand its virtual care program for chronic lung disease across the United States and says it aims to reach tens of thousands of patients over the next two years.
Seattle-based Kivo Health, which provides virtual care for people with chronic lung disease, has raised $10 million in Series A financing to support a planned national expansion. The round, led by Allumia Ventures, brings the company’s total financing to $16 million; Kivo says it aims to serve tens of thousands of patients over the next two years.
The round also included Corewell Health Ventures, Y Combinator, Heuristic Capital and MassMutual Ventures, according to Home Health Care News. The report said Kivo intends to use the new capital to expand its reach nationally and later extend its care model beyond chronic obstructive pulmonary disease, or COPD, to other high-cost chronic illnesses. The company did not disclose additional financial terms in the material provided.
Kivo combines home-use technology with individual treatment plans. After enrolling, a patient receives a kit that includes a tablet, an oxygen monitor and exercise bands, then meets virtually with a respiratory therapist to discuss symptoms and develop a plan. According to the company’s website, participants subsequently meet in small groups with respiratory therapists twice weekly for nine weeks, with sessions focused on breathing techniques, targeted exercises and COPD-management resources.
The service is covered by Medicare, Medicaid and several commercial health plans, including UnitedHealthcare, Humana, Blue Cross, Aetna and Priority Health, according to the report. Kivo says its program has delivered tens of thousands of sessions and reached thousands of patients. Those figures and the company’s stated effects on health-care use are company-reported, rather than independently verified in the source material.
Funding Supports Broader COPD Access
The financing gives Kivo capital to pursue a larger footprint for a care model that brings respiratory therapy into patients’ homes through remote appointments and supplied equipment. For people managing COPD between clinical visits, the company’s approach is designed to provide recurring support without requiring every session to take place in a clinic. Whether the planned expansion translates into meaningful access will depend on where the service becomes available and how patients and health plans use it.
Kivo says its program can reduce hospitalizations, emergency visits and nursing-home days, and it claims to lower total health-care spending by $8,245 per member per year. That is a company-reported estimate; the provided report does not describe the methodology, comparison group or study period behind it. The figure should not be treated as an independently established outcome based on the available information.
Products Worth Considering
Bowflex SelectTech 840 Adjustable Kettlebell
BowFlex Results Series SelectTech Adjustable Dumbbells, Pair
Oura Ring 5 Smart Ring, Silver, Size 7
As an affiliate, we earn on qualifying purchases.
How Kivo’s Home Program Works
Kivo’s initial focus is chronic obstructive pulmonary disease, a long-term lung condition that can require ongoing symptom management and support. The company’s service pairs remote respiratory-therapy sessions with equipment used at home, aiming to help participants work on care plans outside the schedule of traditional appointments. The source material describes the company’s intended model but does not provide clinical-trial results or independent evaluations of its impact.
The company’s reported payer coverage may shape its ability to grow beyond its existing reach. Coverage is listed for public programs and multiple commercial insurers, but the report does not specify which plans, geographic areas or eligibility requirements apply in each case. Kivo’s funding announcement comes with a stated ambition to expand nationwide and eventually address other high-cost chronic conditions, rather than a disclosed timetable for launching those additional programs.
“We have delivered tens of thousands of sessions, providing thousands of patients access to care that improves symptoms and saves health plans money by reducing unnecessary hospitalizations, ER visits and nursing home days.”
— Victor Sadauskas, Kivo Health co-founder and CEO, in an email to Home Health Care News
Expansion Details Still Undisclosed
The announcement does not specify which markets Kivo will enter first, how the $10 million will be allocated, or when nationwide availability is expected. It also does not give a detailed timeline for expanding beyond COPD or identify which additional conditions the company may target.
The source report presents Kivo’s patient counts, cost-savings estimate and reported benefits as company statements. It does not provide independent outcome data, the underlying methodology for the $8,245 annual savings claim, or details about the patient population and timeframe used to calculate it. The scope of insurance coverage and any restrictions on eligibility also remain unspecified.
Kivo’s Two-Year Patient Target
Kivo says it intends to use the financing to expand nationwide and provide care to tens of thousands of patients within two years. The company has also said it plans to adapt its model for other high-cost chronic illnesses. The provided report does not identify launch dates, target states or those conditions, so the next concrete indicators will be where the service becomes available and whether Kivo publishes further details about its rollout and outcomes.
Key Questions
How much funding did Kivo Health raise?
Kivo raised $10 million in Series A financing. The round brings its overall financing to $16 million, according to Home Health Care News.
Who led the Series A round?
Allumia Ventures led the round. Corewell Health Ventures, Y Combinator, Heuristic Capital and MassMutual Ventures also participated, according to the report.
What care does Kivo provide?
Kivo provides virtual home care focused initially on COPD. Its program combines a home kit with virtual respiratory-therapy appointments, including small-group sessions described by the company as taking place twice a week for nine weeks.
What does Kivo plan to do with the new funding?
The company says it will use the financing to expand nationally and aims to reach tens of thousands of patients over the next two years. It also intends to extend its care model to other high-cost chronic illnesses, but has not named those conditions or provided a launch schedule.
Are Kivo’s reported cost savings independently verified?
The source report attributes the estimate of $8,245 in lower annual health-care spending per member to Kivo. It does not provide independent verification or explain the calculation’s methodology, comparison group or timeframe.
Source: homehealthcarenews.com
